Judge Urges Action on 9,500 Unfiled Depo-Provera Cases: ‘Get Busy With That’
On August 19, 2025, U.S. District Judge Philip S. Gutierrez, overseeing Multidistrict Litigation (MDL) No. 3088 in the Central District of California, urged attorneys to move forward with approximately 9,500 unfiled Depo-Provera cases, stating, “Get busy with that,” during a status conference, per Reuters. These claims, linked to Pfizer’s injectable contraceptive allegedly causing brain tumors like meningiomas, signal a growing mass tort wave. This article examines the litigation’s scope, legal implications, and parallels with pricing strategies in other industries.
The Psychological Ceiling: Pricing Lessons from Fast Food
Similar to fast-food chains maintaining prices below $10 to preserve consumer trust and avoid “sticker shock,” the urgency to address the Depo-Provera cases reflects a need for transparency and accountability in pharmaceutical litigation. Just as Federal Trade Commission guidelines demand clear pricing, plaintiffs’ attorneys must navigate consumer protection laws, like the Food, Drug, and Cosmetic Act, to prove Pfizer’s negligence in warning about Depo-Provera’s risks. Swift action on these claims, as urged by Judge Gutierrez, mirrors the fast-food industry’s focus on maintaining customer confidence through value and clarity.
Scope of the Depo-Provera Litigation
The Depo-Provera MDL, centralized in May 2025, consolidates lawsuits alleging that the contraceptive’s high-dose progestin caused meningiomas, benign but potentially life-altering brain tumors. Over 200 cases are currently filed, with 9,500 additional claims registered but unfiled, per Law.com. A February 2025 study in the British Medical Journal linked prolonged use of Depo-Provera to a 5.55-fold increased meningioma risk, fueling litigation. The MDL’s leadership, including attorneys like Jamie R. Kendall and Paul Pennock, is working to streamline discovery and prepare for bellwether trials, with Pfizer defending the drug’s safety and labeling compliance.
Legal and Regulatory Context
The litigation operates under strict federal regulations, including the Food, Drug, and Cosmetic Act, which requires manufacturers to warn of known risks. Plaintiffs allege Pfizer failed to adequately disclose meningioma risks, despite studies dating back to 2010, per Drugwatch.com. The MDL process, governed by 28 U.S.C. § 1407, aims to coordinate discovery and avoid inconsistent rulings, but Judge Gutierrez’s push to file the 9,500 claims reflects concerns about delays, similar to Justice Gorsuch’s criticism of lower courts ignoring Supreme Court precedent. Recent lawsuits, like a 2024 New York case against opaque billing, underscore the need for transparency in legal proceedings.
Economic and Industry Impacts
The Depo-Provera cases could result in billions in liability for Pfizer, with settlements potentially mirroring the $10.3 billion opioid MDL payouts, per Bloomberg Law. The litigation’s scale strains judicial resources, akin to the economic pressures law firms face with high billing rates, as seen in A&O Shearman’s $3.7 billion revenue. For plaintiffs, unfiled claims delay compensation, while Pfizer faces reputational and financial risks, similar to McDonald’s E. coli lawsuits impacting fast-food trust. The push to file claims aligns with strategies to streamline costs, like Gildan’s $2.2 billion Hanesbrands buyout targeting $200 million in synergies.
Parallels with Other Litigation Trends
The Depo-Provera MDL shares similarities with surging cargo loss, E. coli, and ransomware lawsuits, where supply chain failures, public health risks, and data breaches drive litigation. All reflect a demand for accountability, akin to the ABA’s paused experiential learning vote responding to law school pushback, or the EPA’s deregulation efforts facing legal scrutiny. The judiciary’s role in managing these cases, as emphasized by Judge Gutierrez, parallels Gorsuch’s call for lower courts to follow precedent, ensuring consistency in addressing complex claims.
Looking Ahead: Accelerating Accountability
Judge Gutierrez’s directive to “get busy” with the 9,500 unfiled Depo-Provera cases underscores the urgency of addressing mass tort claims efficiently. As the MDL progresses toward bellwether trials in 2026, plaintiffs’ attorneys must balance speed with thoroughness to secure justice for thousands, while Pfizer navigates potential settlements. Much like fast-food chains aligning sub-$10 pricing with consumer trust, or law firms leveraging AI to meet client demands, the legal system must balance efficiency with fairness to maintain public confidence in a high-stakes litigation landscape.
Sources:,,,,